WINT - Windtree Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.05
0.00 (0.00%)
As of 3:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.05
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,116
Market Cap11.292M
Beta1.44
PE Ratio (TTM)N/A
EPS (TTM)-71.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.30
Trade prices are not sourced from all markets
  • Windtree Therapeutics Announces Closing of $2.6 Million Private Placement
    PR Newswire19 days ago

    Windtree Therapeutics Announces Closing of $2.6 Million Private Placement

    WARRINGTON, Pa., April 4, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has closed a $2.6 million private placement of common stock and warrants with a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited at a purchase price of $4.80 per share. In connection with this offering, the Company issued 541,667 shares of common stock and warrants to purchase 135,417 shares of common stock at an exercise price of $5.52 per share. The warrants may be exercised starting six months after the closing date and through the seventh anniversary of such closing date.

  • PR Newswirelast month

    Windtree and Eleison Announce Collaboration to Explore Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Aerosol Delivery System (ADS)

    WARRINGTON, Pa., March 12, 2018 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, today jointly announced a strategic collaboration to assess the feasibility of using Windtree's proprietary pulmonary aerosol delivery system (ADS) to deliver Eleison's inhaled lipid cisplatin (ILC) potentially in combination with Windtree's KL4 surfactant.

  • PR Newswire4 months ago

    Windtree Therapeutics to Provide AEROSURF® and Business Updates

    Conference Call Scheduled for Thursday, January 4, 2018 at 8:00 a.m. Eastern Time Updated Data on AEROSURF Phase 2a clinical trial in 26-28 week GA infants and Phase 2 Program Summary 2018 Objectives and ...

  • Windtree Therapeutics Announces Reverse Stock Split
    PR Newswire4 months ago

    Windtree Therapeutics Announces Reverse Stock Split

    WARRINGTON, Pa., Dec. 21, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced a 1-for-20 reverse stock split of its issued and outstanding common stock. The Company's common stock will begin trading on a split-adjusted basis at the opening of the OTCQB® Market on Friday, December 22, 2017 under the symbol "WINTD".  After 20 trading days, the symbol will revert to WINT.  Effective with the reverse split, a new CUSIP number of 97382D 204 has been assigned to the Company's common stock.

  • PR Newswire4 months ago

    Windtree Therapeutics to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018

    WARRINGTON, Pa. , Dec. 12, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Therapeutics Reports Third Quarter 2017 Financial Results
    PR Newswire5 months ago

    Windtree Therapeutics Reports Third Quarter 2017 Financial Results

    WARRINGTON, Pa. , Nov. 14, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Successfully Completes Financial Restructuring Program
    PR Newswire6 months ago

    Windtree Successfully Completes Financial Restructuring Program

    WARRINGTON, Pa. and SHATIN, HONG KONG, Nov. 1, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and LPH Investments Limited ("LPHIL"), a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm," SEHK Stock Code: 0950), today announced that they have completed a financial restructuring of Windtree that includes a purchase by Lee's Pharm via LPHIL of $10 million of Windtree's common stock, giving Lee's Pharm a controlling interest in Windtree, and a simultaneous restructuring and retirement of $25 million of long-term debt under the 2013 secured loan facility agreement between Windtree and affiliates of Deerfield Management Company, L.P. ("Deerfield"). The completion of these transactions improves Windtree's balance sheet and better positions the Company to raise the capital needed to fund continued development of AEROSURF® for respiratory distress syndrome (RDS) and potentially its pipeline of surfactant products utilizing its proprietary KL4 surfactant and aerosol device technologies.

  • Capital Cube8 months ago

    ETFs with exposure to Windtree Therapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Windtree Therapeutics, Inc. Here are 5 ETFs with the largest exposure to WINT-US. Comparing the performance and risk of Windtree Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube8 months ago

    Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Windtree Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Windtree Therapeutics, Inc. – Aradigm Corporation, Rigel Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Innoviva, Inc., Johnson & Johnson, Pharmaxis Ltd Sponsored ADR, AbbVie, Inc., AmerisourceBergen Corporation and Acura Pharmaceuticals, ... Read more (Read more...)

  • Windtree Therapeutics Reports Second Quarter 2017 Financial Results
    PR Newswire8 months ago

    Windtree Therapeutics Reports Second Quarter 2017 Financial Results

    WARRINGTON, Pa. , Aug. 21, 2017 /PRNewswire/ --   Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, ...

  • PR Newswire8 months ago

    Windtree Announces Initiation of Financial Restructuring Program

    WARRINGTON, Pa., Aug. 18, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated a financial restructuring program intended to result in an improved capital structure, which will better enable the Company to raise the necessary additional capital to fund its AEROSURF® respiratory distress syndrome (RDS) program and further develop its pipeline of surfactant products utilizing its proprietary KL4 and aerosol device technologies. As the initial step in this program, the Company has entered into a loan agreement with Lee's Pharmaceutical (HK) Limited ("Lee's"), pursuant to which Lee's has agreed to advance up to $3.9 million that will be funded at Lee's discretion in three equal installments in August, September and October, 2017, to support AEROSURF® development activities and sustain the Windtree's operations through October 31, 2017, while the parties negotiate a share purchase agreement for Lee's to acquire a controlling interest in Windtree.

  • Windtree Therapeutics and Lee's Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia
    PR Newswire10 months ago

    Windtree Therapeutics and Lee's Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia

    WARRINGTON, Pa. and SHATIN, Hong Kong, June 12, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm", SEHK Stock Code: 0950), today announced that they have entered into an exclusive license and collaboration agreement for the development and commercialization of KL4 surfactant products in select Asian markets using Windtree's proprietary KL4 surfactant and aerosolization technologies. The agreement includes AEROSURF® as well as the non-aerosol products SURFAXIN® (approved in the U.S.) and SURFAXIN LS (an improved lyophilized formulation of SURFAXIN).  Also, Windtree has granted Lee's an exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products in the licensed territory.

  • Windtree Announces Successful Completion of Enrollment in AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants
    PR Newswire11 months ago

    Windtree Announces Successful Completion of Enrollment in AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants

    WARRINGTON, Pa., June 1, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial
    PR Newswire11 months ago

    Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial

    WARRINGTON, Pa., May 22, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has been awarded $0.9 million under a previously announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to $2.6 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support the AEROSURF® phase 2b clinical trial in respiratory distress syndrome (RDS). Windtree was awarded an initial $1.0 million under this grant in August 2016, and over the next year may be awarded up to an additional $0.7 million through the completion of the phase 2b clinical trial and one-year patient follow-up.

  • Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
    Capital Cube11 months ago

    Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017

    Categories: Yahoo FinanceGet free summary analysis Windtree Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Windtree Therapeutics, Inc. – Aradigm Corporation, Rigel Pharmaceuticals, Inc., Idera Pharmaceuticals, Inc., Innoviva, Inc., Johnson & Johnson, AbbVie, Inc., AmerisourceBergen Corporation and Acura Pharmaceuticals, Inc. (ARDM-US, RIGL-US, IDRA-US, ... Read more (Read more...)

  • Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates
    PR Newswire11 months ago

    Windtree Therapeutics Reports First Quarter 2017 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., May 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...

  • Windtree Receives Notice of Delisting from NASDAQ
    PR Newswirelast year

    Windtree Receives Notice of Delisting from NASDAQ

    WARRINGTON, Pa., May 3, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...